Amgevita®

Biosimilar medicine authorized by the AEMPS

Amgevita®

ACTIVE PRINCIPLE:
Adalimumab

INDICATION:
Rheumatoid Arthritis
Juvenile idiopathic arthritis
axial spondylitis
Psoriasic arthritis
Psoriasis
Pediatric plaque psoriasis
Hidradenitis suppurativa
Crohn's disease
Pediatric Crohn's disease
Ulcerative colitis
Uveitis
pediatric uveitis

DATE:
13/04/2018

STATUS:
Authorized


MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE